Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia

Click to increase image sizeClick to decrease image size

Acknowledgements

We thank Novartis Canada for a compassionate supply of nelarabine, Janssen Canada for a compassionate supply of daratumumab and Jazz Pharmaceuticals Canada for a compassionate supply of defibrotide.

Author contributions

JF wrote the paper. PB prepared and contributed the images. CB, GC, PAJV and MS reviewed and revised the paper. All authors approved the final version of the paper.

Disclosure statement

JF has received honoraria from Amgen, Pfizer and Jazz Pharmaceuticals.

PB has received honoraria from Astellas, Novartis, Janssen and Diaceutics.

GC has no relevant conflicts of interest to declare.

PAJV has no relevant conflicts of interest to declare.

CB has received honoraria from Jazz Pharmaceuticals, Novartis and Kite Gilead.

M. Sabloff has updated his coi as follow: MS has received honoraria from Bristol Myers Squibb, Astellas, Pfizer, Celgene, Jazz Pharmaceuticals, Abbvie, Taiho, Roche and Novartis.